Literature DB >> 11334988

Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis.

M Filippi1, M Inglese.   

Abstract

Diffusion-weighted magnetic resonance imaging (DW-MRI) provides a unique form of MR contrast that enables the diffusional motion of water molecules to be quantitatively measured. As a consequence, DW-MRI provides information about the size, shape, integrity, and orientation of brain structures. Pathological processes able to alter tissue integrity by removing or modifying some of the structural barriers that normally restrict water molecular motion in biological tissues cause changes in water diffusion characteristics, which can be measured in-vivo using DW-MRI. Although DW-MRI has been shown to be of great clinical utility in the assessment of patients with cerebral ischemia, it is also increasingly being used to quantify in-vivo the extent and severity of multiple sclerosis (MS) pathology. The pathological elements of MS have the potential to alter the permeability or geometry of structural barriers to water molecular motion in the brain, optic nerve and spinal cord. The present review outlines the major contributions given by DW-MRI for the quantification of MS-related damage and for the understanding of MS pathophysiology.

Entities:  

Mesh:

Year:  2001        PMID: 11334988     DOI: 10.1016/s0022-510x(01)00489-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.

Authors:  Massimo Filippi; Maria A Rocca; Marco Rovaris
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

3.  A diffusion longitudinal MR imaging study in normal-appearing white matter in untreated relapsing-remitting multiple sclerosis.

Authors:  F G Garaci; V Colangelo; A Ludovici; F Gaudiello; S Marziali; D Centonze; L Boffa; G Simonetti; R Floris
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

Review 4.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 5.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

6.  Ultrashort echo time (UTE) magnetic resonance imaging of myelin: technical developments and challenges.

Authors:  Ya-Jun Ma; Hyungseok Jang; Eric Y Chang; Annie Hiniker; Brian P Head; Roland R Lee; Jody Corey-Bloom; Graeme M Bydder; Jiang Du
Journal:  Quant Imaging Med Surg       Date:  2020-06

7.  Magnetic Resonance Imaging Findings in the Pregeniculate Visual Pathway in Leber Hereditary Optic Neuropathy.

Authors:  Juan Zhao; Qing Zhang; Jiawei Wang
Journal:  J Neuroophthalmol       Date:  2021-08-17       Impact factor: 4.415

8.  Improving cervical spinal cord lesion detection in multiple sclerosis using filtered fused proton density-T2 weighted images.

Authors:  Khalid O Alharbi; Abdullah H Abujamea; Othman I Alomair; Hussein M Alsakkaf; Abdulaziz A Alharbi; Sami A Alghamdi; Abdullah G Alharbi
Journal:  Acta Radiol Open       Date:  2022-06-02

9.  Reproducibility of brain ADC histograms.

Authors:  Stefan C A Steens; Faiza Admiraal-Behloul; Jorrit A Schaap; Frank G C Hoogenraad; Claudia A M Wheeler-Kingshott; Saskia le Cessie; Paul S Tofts; Mark A van Buchem
Journal:  Eur Radiol       Date:  2003-11-14       Impact factor: 5.315

10.  Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis.

Authors:  Simon J Hickman; Claudia A M Wheeler-Kingshott; Stephen J Jones; Katherine A Miszkiel; Gareth J Barker; Gordon T Plant; David H Miller
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.